OncoMatch/Clinical Trials/NCT03832127
Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients
Is NCT03832127 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies 18F-Fludarabine for myeloma.
Treatment: 18F-Fludarabine — The objective of this exploratory study is to evaluate, for the first time, the sensitivity of 18F-Fludarabine to the initial diagnosis of MM compared to FDG-PET and MRI. The interest of this molecule will also be investigated as part of the end-of-treatment therapeutic evaluation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Performance status
KARNOFSKY/ECOG 0–1
Karnofsky ≥ 70 or ECOG 0-1
Prior therapy
Lab requirements
Blood counts
neutropenia < 1000 PN/mm3; thrombocytopenia < 70,000/mm3 [excluded]
Kidney function
creatinine clearance < 50 ml/min [excluded]
Liver function
bilirubin > 35μmol/L and SGOT, SGPT, alkaline phosphatase greater than 3 N [excluded]
Neutropenia <1000 PN / mm3; Thrombocytopenia <70,000 / mm3; Hepatic impairment: bilirubin> 35μmol / L and SGOT, SGPT, alkaline phosphatase greater than 3 N; Renal impairment defined by creatinine clearance <50 ml / min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03832127 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages